In addition to anticancer vaccines, cytokines, and immune checkpoint inhibitors, bispecific T cell engagers (BiTE) antibody (Ab) constructs, and chimeric antigen receptor T cells (CAR-T cells) represent alternative methods for harnessing the immune system to fight cancer. Whereas immune checkpoint inhibitors amplify antigen-specific T cell response, BiTEs provide assistance in increasing T cell activity, and CAR-T cell therapy augments the capabilities of T cells.
The field of CAR-T has grown significantly in recent years; there have been over 800 publications on CAR-T cells within the past five years and many clinical trials showing success, particularly for B cell malignancies. The field is led by companies such as Novartis, Juno Therapeutics, Kite Pharma, and Bluebird Bio, but CAR-T therapies have yet to reach the market.
Click for full report: A Primer on Immuno-Oncolgoy: Part 2 – Targeted Redirection of T Cells
This report will provide a brief overview of BiTEs, as well as a more comprehensive review of CAR-T cell therapy. This report is part two of Kineticos’ series of research reports on cancer immunotherapies. Below are a few key topics addressed in the report:
- BiTEs
- CAR-T Cell Therapies
- Key Players in the CAR-T Cell space
- Scientific and Other Challenges faced by CAR-T Cell therapies
